Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Abstract B025: Integrative omics analysis decodes cross-talk between signaling pathways to understand the anti-cancer mechanism of TKIs in NSCLC

Guolin Zhang, Karen Ross, Cuneyt Akcora, Katia Smirnova, Bin Fang, John M. Koomen, Eric B. Haura, Mark Grimes

Mol Cancer Ther (2019) 18 (12_Supplement): B025.

https://doi.org/10.1158/1535-7163.TARG-19-B025

Published: 01 December 2019

View articletitled, Abstract B025: Integrative omics analysis decodes cross-talk between signaling pathways to understand the anti-cancer mechanism of TKIs in NSCLC

Journal Articles

Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC

Vinayak Palve, Clare Knezevic, Yunting Luo, Xueli Li, Slivia Novakova, Eric Welsh, Bin Fang, Fumi Kinose, Eric B Haura, Alvaro N Monteiro, John M Koomen, Harshani R Lawrence, Uwe Rix

Mol Cancer Ther (2019) 18 (12_Supplement): B021.

https://doi.org/10.1158/1535-7163.TARG-19-B021

Published: 01 December 2019

View articletitled, Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC

Journal Articles

Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells

Lily L. Remsing Rix, Natalia J. Sumi, Annamarie T. Bryant, Xueli Li, Eric A. Welsh, Bin Fang, Brent M. Kuenzi, Scott J. Antonia, Andriy Marusyk, Christine M. Lovly, John M. Koomen, Eric B. Haura, Uwe Rix

Mol Cancer Ther (2019) 18 (12_Supplement): C110.

https://doi.org/10.1158/1535-7163.TARG-19-C110

Published: 01 December 2019

View articletitled, Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells

Journal Articles

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Ankita Jhuraney, Nicholas T. Woods, Gabriela Wright, Lily Rix, Fumi Kinose, Jodi L. Kroeger, Elizabeth Remily-Wood, W. Douglas Cress, John M. Koomen, Stephen G. Brantley, Jhanelle E. Gray, Eric B. Haura, Uwe Rix, Alvaro N. Monteiro

Mol Cancer Ther (2016) 15 (7): 1669–1681.

https://doi.org/10.1158/1535-7163.MCT-15-0182

Published: 05 July 2016

View articletitled, PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Includes: Supplementary data

Journal Articles

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Jiannong Li, Bin Fang, Fumi Kinose, Yun Bai, Jae-Young Kim, Yian A. Chen, Uwe Rix, John M. Koomen, Eric B. Haura

Mol Cancer Ther (2016) 15 (2): 334–342.

https://doi.org/10.1158/1535-7163.MCT-15-0444

Published: 07 February 2016

View articletitled, Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Includes: Supplementary data

Journal Articles

Abstract LB-C12: Functional proteomics elucidates signaling adaptation driven by combination therapy in BRAF mutant melanoma cell line models

Ritin Sharma, Inna Fedorenko, Sasa Koncarevic, Vikram Mitra, Stefan Selzer, Gitte Boehm, Ian Pike, Keiran Smalley, John M. Koomen

Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C12.

https://doi.org/10.1158/1535-7163.TARG-15-LB-C12

Published: 01 December 2015

View articletitled, Abstract LB-C12: Functional proteomics elucidates signaling adaptation driven by combination therapy in BRAF mutant melanoma cell line models

Journal Articles

MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma

Anthony W. Gebhard, Priyesh Jain, Rajesh R. Nair, Michael F. Emmons, Raul F. Argilagos, John M. Koomen, Mark L. McLaughlin, Lori A. Hazlehurst

Mol Cancer Ther (2013) 12 (11): 2446–2458.

https://doi.org/10.1158/1535-7163.MCT-13-0310

Published: 06 November 2013

View articletitled, MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma

Includes: Supplementary data

Journal Articles

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

H. Eirik Haarberg, Kim H.T. Paraiso, Elizabeth Wood, Vito W. Rebecca, Vernon K. Sondak, John M. Koomen, Keiran S.M. Smalley

Mol Cancer Ther (2013) 12 (6): 901–912.

https://doi.org/10.1158/1535-7163.MCT-12-1003

Published: 09 June 2013

View articletitled, Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract B025: Integrative omics analysis decodes cross-talk between signaling pathways to understand the anti-cancer mechanism of TKIs in NSCLC

Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC

Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Abstract LB-C12: Functional proteomics elucidates signaling adaptation driven by combination therapy in BRAF mutant melanoma cell line models

MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only